Literature DB >> 8485912

C1 inhibitor functional deficiency in systemic lupus erythematosus (SLE).

E C Jazwinska1, P A Gatenby, H Dunckley, S W Serjeantson.   

Abstract

C1 inhibitor (C1-inh) was assayed in eight SLE patients presenting with consistently low levels of intact C4. C1-inh antigenic levels were normal in all patients; however, the function of the C1-inh tested against C1s and C1r was variable and outside the normal functional range in seven of the eight patients. The molecular weight of patients' C1-inh protein was 105 kD, corresponding to the size of the intact molecule. The C1-inh gene was analysed in all patients. Restriction fragments generated with TaqI, PstI and HgiAI gave no indication of a major C1-inh gene rearrangement. Direct genomic sequencing of exon VIII revealed three polymorphic point mutations, but there were no changes from the normal gene in or around the reactive-centre residue of C1-inh. Furthermore, we found no evidence for a C1-inh autoantibody in patients which could affect normal C1-inh function in vitro. These results indicate that the etiology of C1-inh dysfunction in SLE is heterogeneous and distinct from that reported in either hereditary or acquired angioedema.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8485912      PMCID: PMC1554798          DOI: 10.1111/j.1365-2249.1993.tb03391.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  15 in total

1.  Demonstration of modified inactive first component of complement (C1) inhibitor in the plasmas of C1 inhibitor-deficient patients.

Authors:  B L Zuraw; J G Curd
Journal:  J Clin Invest       Date:  1986-08       Impact factor: 14.808

2.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

3.  Fc gamma RII restriction fragment length polymorphism (RFLP): analysis in systemic lupus erythematosus and scleroderma and evidence of an alpha gene duplication.

Authors:  E C Jazwinska; C Olive; P M Hogarth; P A Gatenby; S W Serjeantson
Journal:  Clin Exp Immunol       Date:  1991-01       Impact factor: 4.330

4.  Genetic heterogeneity of the B subunit of coagulation factor XIII: resolution of type 2.

Authors:  P G Board
Journal:  Ann Hum Genet       Date:  1984-07       Impact factor: 1.670

5.  Polymorphism of the human complement C4 and steroid 21-hydroxylase genes. Restriction fragment length polymorphisms revealing structural deletions, homoduplications, and size variants.

Authors:  P M Schneider; M C Carroll; C A Alper; C Rittner; A S Whitehead; E J Yunis; H R Colten
Journal:  J Clin Invest       Date:  1986-09       Impact factor: 14.808

6.  An IgG autoantibody which inactivates C1-inhibitor.

Authors:  J Jackson; R B Sim; A Whelan; C Feighery
Journal:  Nature       Date:  1986 Oct 23-29       Impact factor: 49.962

7.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

8.  Autoantibody-mediated acquired deficiency of C1 inhibitor.

Authors:  J Alsenz; K Bork; M Loos
Journal:  N Engl J Med       Date:  1987-05-28       Impact factor: 91.245

9.  Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization.

Authors:  S C Bock; K Skriver; E Nielsen; H C Thøgersen; B Wiman; V H Donaldson; R L Eddy; J Marrinan; E Radziejewska; R Huber
Journal:  Biochemistry       Date:  1986-07-29       Impact factor: 3.162

10.  Variability in purified dysfunctional C1(-)-inhibitor proteins from patients with hereditary angioneurotic edema. Functional and analytical gel studies.

Authors:  V H Donaldson; R A Harrison; F S Rosen; D H Bing; G Kindness; J Canar; C J Wagner; S Awad
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

View more
  2 in total

Review 1.  Acquired angioedema in juvenile systemic lupus erythematosus: case-based review.

Authors:  Zahide Ekici Tekin; Gülçin Otar Yener; Selçuk Yüksel
Journal:  Rheumatol Int       Date:  2018-06-27       Impact factor: 2.631

2.  Dramatic development of severe SLE in a patient with an incomplete disease.

Authors:  G Fabio; M Carrabba; C Hu; M Floriani; C Besana
Journal:  Rheumatol Int       Date:  2005-01-21       Impact factor: 2.631

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.